XRAY
Overvalued by 3.1% based on the discounted cash flow analysis.
Market cap | $5.88 Billion |
---|---|
Enterprise Value | $7.67 Billion |
Dividend Yield | $0.5726 (2.02%) |
Earnings per Share | $-0.62 |
Beta | 0.86 |
Outstanding Shares | 207,363,276 |
Avg 30 Day Volume | 2,693,208 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -44.58 |
---|---|
PEG | 8.16 |
Price to Sales | 1.46 |
Price to Book Ratio | 1.85 |
Enterprise Value to Revenue | 1.93 |
Enterprise Value to EBIT | 26.91 |
Enterprise Value to Net Income | -59 |
Total Debt to Enterprise | 0.28 |
Debt to Equity | 0.64 |
No data
No data